Todd E. Manahan

Array ( [id] => 16389665 [patent_doc_number] => 20200330606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => MODULATION OF STRUCTURAL MAINTENANCE OF CHROMOSOME-1 EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/090043 [patent_app_country] => US [patent_app_date] => 2017-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14574 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16090043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11821884 [patent_doc_number] => 20170210820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'HUMAN ANTIBODIES AND PROTEINS' [patent_app_type] => utility [patent_app_number] => 15/471290 [patent_app_country] => US [patent_app_date] => 2017-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 19230 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15471290 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14156601 [patent_doc_number] => 20190105403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => METHODS FOR SELECTING ANTIBODIES THAT SPECIFICALLY BIND GLYCOSYLATED IMMUNE CHECKPOINT PROTEINS [patent_app_type] => utility [patent_app_number] => 16/086574 [patent_app_country] => US [patent_app_date] => 2017-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37074 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -62 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16086574 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971199 [patent_doc_number] => 20170275353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'TRISPECIFIC INHIBITORS FOR CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 15/467744 [patent_app_country] => US [patent_app_date] => 2017-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 24251 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15467744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11821888 [patent_doc_number] => 20170210825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-27 [patent_title] => 'MONOSPECIFIC AND MULTISPECIFIC ANTIBODIES AND METHOD OF USE' [patent_app_type] => utility [patent_app_number] => 15/466587 [patent_app_country] => US [patent_app_date] => 2017-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 14157 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15466587 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15483243 [patent_doc_number] => 10556954 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-11 [patent_title] => Anti-PD-L1 nanobody, coding sequence and use thereof [patent_app_type] => utility [patent_app_number] => 16/085899 [patent_app_country] => US [patent_app_date] => 2017-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 7976 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16085899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12975961 [patent_doc_number] => 20170340737 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => INTERLEUKIN -13 BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 15/457264 [patent_app_country] => US [patent_app_date] => 2017-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 118 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15457264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11836348 [patent_doc_number] => 20170218067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-03 [patent_title] => 'Antibodies Against T Cell Immunoglobulin Domain and Mucin Domain 1 (TIM-1) Antigen and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 15/442083 [patent_app_country] => US [patent_app_date] => 2017-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 30457 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15442083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11942123 [patent_doc_number] => 20170246274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-31 [patent_title] => 'IMMUNOGENIC POLYPEPTIDE COCKTAIL FOR THE TREATMENT OF MEDULLARY THYROID CARCINOMA' [patent_app_type] => utility [patent_app_number] => 15/436525 [patent_app_country] => US [patent_app_date] => 2017-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 20034 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15436525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16246136 [patent_doc_number] => 10745478 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-18 [patent_title] => Antibody fusion protein and related compositions for targeting cancer [patent_app_type] => utility [patent_app_number] => 15/999241 [patent_app_country] => US [patent_app_date] => 2017-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 10970 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15999241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13898929 [patent_doc_number] => 20190038669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => ANTIBODIES AGAINST N-ACETYLGUCOSAMINE AND N-ACETYL-GALACTOSAMINE [patent_app_type] => utility [patent_app_number] => 15/999337 [patent_app_country] => US [patent_app_date] => 2017-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -136 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15999337 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14501367 [patent_doc_number] => 20190194338 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-27 [patent_title] => BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 15/999346 [patent_app_country] => US [patent_app_date] => 2017-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22042 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -87 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15999346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17451781 [patent_doc_number] => 11266616 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Compositions and methods for inhibiting kinase activity [patent_app_type] => utility [patent_app_number] => 16/075550 [patent_app_country] => US [patent_app_date] => 2017-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 82 [patent_no_of_words] => 140863 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17815429 [patent_doc_number] => 11421028 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-23 [patent_title] => Fabs-in-tandem immunoglobulin and uses thereof [patent_app_type] => utility [patent_app_number] => 16/075922 [patent_app_country] => US [patent_app_date] => 2017-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 75 [patent_no_of_words] => 65402 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 318 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16075922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11627345 [patent_doc_number] => 20170137534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'Anti-Pancreatic Cancer Antibodies' [patent_app_type] => utility [patent_app_number] => 15/422110 [patent_app_country] => US [patent_app_date] => 2017-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 53247 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15422110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11957356 [patent_doc_number] => 20170261508 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'METHODS FOR MONITORING CD4+ T-HELPER TYPE 1 RESPONSE IN CANCER AND IMMUNE RESTORATION' [patent_app_type] => utility [patent_app_number] => 15/417204 [patent_app_country] => US [patent_app_date] => 2017-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 32932 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15417204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14005609 [patent_doc_number] => 10221242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-03-05 [patent_title] => Antibodies specific for epidermal growth factor receptor variant III and their uses [patent_app_type] => utility [patent_app_number] => 15/402807 [patent_app_country] => US [patent_app_date] => 2017-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 32025 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15402807 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464461 [patent_doc_number] => 20190183870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => COMBINATION OF HISTONE DEACETYLASE INHIBITOR AND IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/066693 [patent_app_country] => US [patent_app_date] => 2017-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10340 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16066693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11690918 [patent_doc_number] => 20170166633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-15 [patent_title] => 'ANTIBODIES AGAINST THE RGM A PROTEIN AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/389627 [patent_app_country] => US [patent_app_date] => 2016-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 42605 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15389627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11567404 [patent_doc_number] => 20170106048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-20 [patent_title] => 'Combination of CD95/CD95L inhibition and Cancer Immunotherapy' [patent_app_type] => utility [patent_app_number] => 15/390272 [patent_app_country] => US [patent_app_date] => 2016-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 9814 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15390272 [rel_patent_id] =>[rel_patent_doc_number] =>)